Research on the neonatal consequences of prenatal exposure to buprenorphine is quite limited. - Research on the neonatal consequences of prenatal exposure to buprenorphine is quite limited.
- Not enough births have been followed for a sufficient period of time to collect convincing data regarding factors such as cognitive and social development.
- Same issue of confounding parental and family factors in teasing apart developmental effect.
- Reviews in Jones et al., Drugs, 2012, and Addiction, 2012
MOTHER: Sites - Lead Site Johns Hopkins U PI: H. Jones
- Brown U PI: B. Lester
- Thomas Jefferson U PI: K. Kaltenbach
- U Vermont PI: S. Heil
- U Vienna PI: G. Fischer
- U Toronto PI: P. Selby
- Vanderbilt U PI: P. Martin
- Wayne State U PI: S. Stine
- Coordinating Center PI: A. Arria
- Compared with methadone-exposed neonates, buprenorphine-exposed neonates
- Required 89% less morphine to treat NAS
- Spent 43% less time in the hospital
- Spent 58% less time in the hospital being medicated for NAS
- Both medications in the context of comprehensive care produced similar maternal treatment and delivery outcomes
- Notes: Significant results are encircled. Site was a blocking factor in all analyses. The O’Brien-Fleming α spending function resulted in α = .0091 for the inferential tests of the Medication Condition effect for the 5 primary outcome measures at the conclusion of the trial.
- Jones et al., N Engl J Med. 2010
- MOTHER: Buprenorphine v. Methadone Primary
- Clinically meaningful attrition rate in buprenorphine condition
- Low rates of illicit drug use during pregnancy and at delivery
- Maternal outcomes similar in the 2 study conditions
- Note: Bonferroni’s principle was used to set familywise α = .003125 (nominal α = .05/16) for the secondary outcome measures.
- Jones et al., N Engl J Med. 2010
- Relationship between Methadone Dose and 9 Clinical Neonatal Outcomes (N=73)
| | | | | | | | | | | - Total amount of morphine for NAS (mg)
| | | | | - Duration of treatment for NAS (days)
| | | | | - Duration of neonatal hospital stay (days)
| | | | | - Gestational age at delivery (weeks)
| | | | | | | | | | | | | | | | | - Neonatal head circumference (cm)
| | | | | | | | | | | | | | | | | - Methadone and Buprenorphine: NAS
- Jones et al., Neurotoxicol Teratol, 2013
- Relationship between Buprenorphine Dose and 9 Clinical Neonatal Outcomes (N=58)
| | | | | | | | | | | - Total amount of morphine for NAS (mg)
| | | | | - Duration of treatment for NAS (days)
| | | | | - Duration of neonatal hospital stay (days)
| | | | | - Gestational age at delivery (weeks)
| | | | | | | | | | | | | | | | | - Neonatal head circumference (cm)
| | | | | | | | | | | | | | | | | - Methadone and Buprenorphine: NAS
- Jones et al., Drug Alc Depend, 2014
Share with your friends: |
